Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) EBIT (2022 - 2025)

Historic EBIT for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to -$2.3 million.

  • bioAffinity Technologies' EBIT fell 1616.03% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.4 million, marking a year-over-year decrease of 2434.7%. This contributed to the annual value of -$9.0 million for FY2024, which is 1229.39% down from last year.
  • bioAffinity Technologies' EBIT amounted to -$2.3 million in Q3 2025, which was down 1616.03% from -$2.5 million recorded in Q2 2025.
  • bioAffinity Technologies' EBIT's 5-year high stood at -$684119.0 during Q2 2022, with a 5-year trough of -$2.9 million in Q4 2024.
  • In the last 4 years, bioAffinity Technologies' EBIT had a median value of -$2.0 million in 2024 and averaged -$1.9 million.
  • Its EBIT has fluctuated over the past 5 years, first plummeted by 15994.75% in 2023, then surged by 1397.43% in 2024.
  • Over the past 4 years, bioAffinity Technologies' EBIT (Quarter) stood at -$1.6 million in 2022, then tumbled by 44.26% to -$2.3 million in 2023, then fell by 25.79% to -$2.9 million in 2024, then grew by 22.19% to -$2.3 million in 2025.
  • Its EBIT stands at -$2.3 million for Q3 2025, versus -$2.5 million for Q2 2025 and -$2.6 million for Q1 2025.